Skip to content

Neural origin of slow vision: contributions of the central and peripheral nervous system.

Neural origin of slow vision: contributions of the central and peripheral nervous system. - The origin of slow vision

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON41172
Enrollment
50
Registered
2014-08-28
Start date
2015-06-19
Completion date
Unknown
Last updated
2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

slow vision slow visual processing speed

Interventions

None listed

Sponsors

Radboudumc
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Between 18 and 65 years old - Visual acuity >= 0.6 - Normal birth weight (i.e. >= 2500 g) and pregnancy duration (i.e. >= 37 weeks);Patients: Probable slow vision: Complaints related to slow visual processing, for example: - Reading slowly - Being unable to read subtitles(e.g. during movies) in time (i.e. before they disappear from the screen). - Not being able to quickly find objects in a pile (for example in a full drawer). - Not being able to quickly recognize a face in a crowd. Or, abnormally slow in identifying optotypes during standard ophthalmological examination as assessed by the optometrist/ophthalmologist.

Exclusion criteria

Exclusion criteria: • Any visual field defect in central 30* with statistical significance of more than 0,95, determined with Humphrey perimetry • Ocular surgery other than uneventful cataract surgery, within 3 months before inclusion to our study • Diagnosis of congenital or acquired optic nerve head pathology. • Diagnosis of manifest glaucoma with defects in the visual field. • Diagnosis of a neurodegenerative disorder or high-energy brain trauma.;Patients: Only for mERG: • Presence of contraindications reported by the participant for tropicamide and phenylephrine • Pregnancy or breast feeding • Hypersensitivity to oxybuprocain;Only for MRI and MEG sessions: • Exclusion criteria determined by the Donders Centre for Cognitive Neuroimaging regarding safety and/or signal interference.;Controls: • Presence of contraindications reported by the participant for tropicamide and phenylephrine • Pregnancy or breast feeding • Exclusion criteria determined by the Donders Centre for Cognitive Neuroimaging regarding safety and/or signal interference. • Hypersensitivity to oxybuprocain

Design outcomes

Primary

MeasureTime frame
• Electrophysiological responses of the retina and the cortex to visual stimuli. • Optical responses of the photoreceptors to visual stimuli. • Performance on computer-based tasks testing central vision, visual attention and motion detection. • Electrophysiological and haemodynamic neural responses of the brain to visual stimuli.

Secondary

MeasureTime frame
Diagnostic value of the speed-acuity to discriminate between patients and controls. Auditory processing speed using a computer-based task in order to exclude the possibility that processing speed in general is disrupted in SV rather than specifically in the visual modality.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)